CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Khanna, Anchit, Rane, Jayant K., Kivinummi, Kati K., Urbanucci, Alfonso, Helenius, Merja A., Tolonen, Teemu T., Saramäki, Outi R., Latonen, Leena, Manni, Visa, Pimanda, John E., Maitland, Norman J., Westermarck, Jukka, Visakorpi, Tapio
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4637312/
https://ncbi.nlm.nih.gov/pubmed/25965834
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars